Abstract PO4-12-11: Patient (pt) time burden with IV vs subcutaneous (SC) administration of trastuzumab/pertuzumab (HP): A time and motion (T+M) substudy of a single arm phase II trial of adjuvant endocrine therapy plus HP for stage I HER2+ breast cancer
Waks, Adrienne, Graham, Noah, Chen, Emily, Frey, Anna Mae, Attaya, Victoria, Abbass, Ibrahim, Fung, Anita, Sussell, Jesse, Cortazar, Patricia, Harvey, Caroline, Almeida, Kenneth, Leth, Denise, Chen, Wendy, Leone, Jose, Schumer, Susan, Tayob, Nabihah, Tolaney, Sara
Published in Cancer research (Chicago, Ill.) (02.05.2024)
Published in Cancer research (Chicago, Ill.) (02.05.2024)
Get full text
Journal Article
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
Waks, Adrienne G, Chen, Emily L, Graham, Noah, Frey, Anna Mae, Almeida, Kenneth, Attaya, Victoria, Ryding, Cari, Abbass, Ibrahim, Fung, Anita, Sussell, Jesse, Cortazar, Patricia, Harvey, Caroline, Leth, Denise, Faggen, Meredith, Sinclair, Natalie, Walsh, Jeanna, Tung, Nadine, Sinclair, Sarah, Lo, Steve, Yardley, Denise, Valero, Vicente, Meisel, Jane, Ballinger, Tarah J, Adams, Sylvia, Carey, Lisa A, Rauch, Julia K, Abramson, Vandana G, Williams, Nicole O, Chen, Wendy Y, Leone, Jose P, Schumer, Susan T, Tayob, Nabihah, Tolaney, Sara M
Published in JCO oncology practice (19.07.2024)
Published in JCO oncology practice (19.07.2024)
Get more information
Journal Article